Shares of Fulcrum Therapeutics, Inc. (FULC) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease. Currently, there are no treatments approved for the given indication. The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in rela ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences: Wells Fargo Healthcare Conference Wednesday, September 4, 2024 Boston, MA Morgan Stanley 22nd Annual Global Healthcare Conference Frid ...

Fulcrum Therapeutics, Inc. (FULC) closed the last trading session at $9.42, gaining 6.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.11 indicates a 71% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $5.78. While the lowest estimate of $5 indicates a 46.9% decline from the current price level, the most optimistic anal ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Results Conference Call July 31, 2024 8:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Iain Fraser - SVP of Early Development Conference Call Participants Corinne Johnson - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Dae Gon Ha - Stifel Gregory Renza - RBC Capital Markets Matthew Biegler - Oppenheimer Operator Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other juri ...

• Cash Position: As of June 30, 2024, cash, cash equivalents, and marketable securities were $273.8 million, as compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80.0 million upfront payment received from Sanofi in the second quarter of 2024, partially offset by cash used to fund our operating activities in 2024. • Collaboration Revenue: Collaboration revenue was $80.0 million for the three months ended June 30, 2024, as compared to $0.9 million for the thr ...

― Conference call and webcast scheduled for 8:00 a.m. ET today ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for ...

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company's website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available. CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (Nasdaq: FU ...

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company's website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available. Contact: Chris Calabrese LifeSci Advisors, LLC ccalabrese@lifesciadvisors.com 917-680-5608 CAMBRIDGE, Mass. ...

The presentations to be made are as follows: Title: Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms Presentation Number: S6.06 Format: Oral presentation Presenter: Joost Kools, MD, Radboud University Medical Center Presentation Date and Time: Friday, June 14, 2024 at 3:50 PM MDT Title: Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in Facioscapulohumeral Muscular Dystrophy Poster Number: P7 ...